China To Further Squeeze Distribution Margins And Limit Drug Markups In Hospitals
This article was originally published in The Pink Sheet Daily
The National People’s Congress and Chinese Peoples’ Political Consultative Conference will bring in March a variety of new policies and regulations that will impact the industry.
You may also be interested in...
China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.